 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol
IDs
|
|
|
| |
Recurrence of Bladder Cancer After Transurethral Resection With Hexvix
|
|
|
|
Phase IV
|
|
|
|
GE-196-001
NCT00785694
|
|
| |
Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-Refractory Patients With Non-Muscle Invasive Bladder Cancer
|
|
|
|
Phase III, Phase II
|
|
|
|
HIS-0611-0602
NCT00406068
|
|
| |
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
|
|
|
|
Phase III
|
|
|
|
EORTC-30994
ACOSOG-EORTC-30994, CAN-NCIC-EORTC-30994, FNCLCC-GETUG-EORTC-30994, JUG-EORTC-30994, NORDIC-EORTC-30994, SEUG-EORTC-30994, SWOG-EORTC-30994, UKCCCR-EORTC-30994, NCRI-BLADDER-EORTC-30994, NCT00028756
|
|
| |
Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer
|
|
|
|
Phase III
|
|
|
|
B9E-MC-S062
AB 22/00, NCT00146276
|
|
| |
URO-BCG-4 : Bladder Tumors Immunotherapy
|
|
|
|
Phase III
|
|
|
|
2003/081/HP
NCT00213655
|
|
| |
Study to Investigate the Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients With Bladder Cancer Undergoing Radical or Total Cystectomy
|
|
|
|
Phase III
|
|
|
|
12002
NCT00306150
|
|
| |
Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
|
|
|
|
Phase III
|
|
|
|
SWOG-S0337
S0337, NCT00445601
|
|
| |
Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing TUR-BT
|
|
|
|
Phase III
|
|
|
|
SPI-611
NCT00461591
|
|
| |
Phase 3 Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant for Noninvasive Bladder Cancer
|
|
|
|
Phase III
|
|
|
|
SPI-612
NCT00598806
|
|
| |
Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
|
|
|
|
Phase III
|
|
|
|
EFC6668
EUDRACT: 2007-001943-23, NCT00625664
|
|
